The top candidates included known AML markers CD123 (IL3RA)38, CD105 (Endoglin)39, CD93 (ref. 40), CD369 (CLEC7A)41, IL1RAP42,43 and CD56 (NCAM1)44, as well as multiple novel candidate markers not previously described in AML. Here, NCAM1 is linked to acute myeloid leukemia.